TNG Stock Overview
A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Transgene SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.78 |
| 52 Week High | €1.52 |
| 52 Week Low | €0.76 |
| Beta | 0.80 |
| 11 Month Change | -22.20% |
| 3 Month Change | -25.48% |
| 1 Year Change | -46.64% |
| 33 Year Change | -72.21% |
| 5 Year Change | -59.65% |
| Change since IPO | -98.27% |
Recent News & Updates
Recent updates
Is Transgene (EPA:TNG) Using Too Much Debt?
Jun 15
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
Mar 21Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 19Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Mar 18Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Nov 24Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Apr 16What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Mar 12Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?
Jan 23
Shareholder Returns
| TNG | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -9.0% | -7.7% | -0.3% |
| 1Y | -46.6% | -26.4% | -3.5% |
Return vs Industry: TNG underperformed the French Biotechs industry which returned -26.5% over the past year.
Return vs Market: TNG underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: TNG's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: TNG's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 146 | Alessandro Riva | www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
| TNG fundamental statistics | |
|---|---|
| Market cap | €102.69m |
| Earnings (TTM) | -€22.91m |
| Revenue (TTM) | €6.49m |
15.8x
P/S Ratio-4.5x
P/E RatioIs TNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNG income statement (TTM) | |
|---|---|
| Revenue | €6.49m |
| Cost of Revenue | €29.44m |
| Gross Profit | -€22.95m |
| Other Expenses | -€37.00k |
| Earnings | -€22.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | -353.37% |
| Net Profit Margin | -352.80% |
| Debt/Equity Ratio | -5,956.7% |
How did TNG perform over the long term?
See historical performance and comparison